Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia - Wikidata - awgldk - TriplyDB

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia

http://www.wikidata.org/entity/Q36708123

about

Cerebrospinal fluid biomarkers of Alzheimer’s disease Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria Insulin Resistance is Associated with Higher Cerebrospinal Fluid Tau Levels in Asymptomatic APOEɛ4 Carriers Magneto-immunocapture with on-bead fluorescent labeling of amyloid-β peptides: towards a microfluidized-bed-based operation.Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.Diagnostic value of cerebrospinal fluid Aβ ratios in preclinical Alzheimer's disease Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease.CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.Truncated and modified amyloid-beta species.The Metalloprotease Meprin β Is an Alternative β-Secretase of APP.Selecting Aβ isoforms for an Alzheimer's disease cerebrospinal fluid biomarker panel.Neutral polymers as coatings for high resolution electrophoretic separation of Aβ peptides on glass microchips.Generation and Partial Characterization of Rabbit Monoclonal Antibody to Amyloid-β Peptide 1-37 (Aβ37).Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation.

P2860

Q22252572-14978D43-380A-4FC4-BE4D-E2B56DFFBD9A Q26864063-E1F2BF00-BAFD-4C67-86D2-AA282463843B Q34468797-F452FE30-1DD8-44D6-9667-867220D39795 Q35709581-0C27BEDB-0734-49D4-B855-E460F04279EC Q36157458-3538D401-BEE5-48BF-A891-939AD3DCB3AA Q36383749-85EE643B-21D8-49EB-8C85-A98080C685A2 Q36626657-2FD85960-0043-4FA0-8713-CD27B8AF0BF0 Q36639655-D0C44201-775A-4476-968C-23EF152CAC6D Q38230390-9883B581-6E81-4C10-BC6A-633FC3F8206C Q39095782-6EFCE828-10A3-4BE9-B5B7-5969F58BE6D4 Q39098473-FFB11679-A665-454D-B179-A47EDD4E4103 Q39106083-8111D36B-8433-4A0A-8F5F-38EACE6C7AEE Q48299006-034AFF55-6BAC-422B-9698-7BA1ADD22DD6 Q48824117-FBEEF0D2-48FF-49C7-8416-FC3EABEE4BF6

P2860

Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementia

http://www.wikidata.org/entity/Q36708123

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Cerebrospinal fluid amyloid-β ...... not in frontotemporal dementia

@ast

Cerebrospinal fluid amyloid-β ...... not in frontotemporal dementia

@en

type

label

Cerebrospinal fluid amyloid-β ...... not in frontotemporal dementia

@ast

Cerebrospinal fluid amyloid-β ...... not in frontotemporal dementia

@en

prefLabel

Cerebrospinal fluid amyloid-β ...... not in frontotemporal dementia

@ast

Cerebrospinal fluid amyloid-β ...... not in frontotemporal dementia

@en

P1433

Q36708123-C97A5C8C-6635-464B-9686-AD86398C6300

P1476

Q36708123-D60FBC0C-625C-490E-B56C-7EC93FC1FE4A

P2093

Q36708123-00A267BC-B37F-41D6-BE5E-9F846E8FCFD2

Q36708123-1BBC3541-718C-45E4-A2D2-2590BEA40DB9

Q36708123-A4D4DBB9-BE63-438A-825F-B0D93EDF5EDC

Q36708123-B8DB16B9-AEF6-4D59-B474-CCF2F184BD23

Q36708123-C822D600-F592-4494-A4F6-11A638E13DF1

Q36708123-E5FAEBC6-2858-416C-B157-9A31F887DB28

P2860

Q36708123-03EF4349-BEAD-4E1E-9516-284FC835BD2A

Q36708123-14327C64-0484-448D-92AA-748C40A4B7F4

Q36708123-24908037-D287-4B44-815B-C3241DD05FC1

Q36708123-2865A71E-63B2-4B11-BF72-7C87FDE8598C

Q36708123-36FE6170-15BC-43AE-A693-0480318CB5AF

Q36708123-3F25AD59-F20E-4264-8F34-BD7264596C1C

Q36708123-3F999C69-41E7-46F5-93DC-03E41C372DE2

Q36708123-4417C030-56D8-43AB-ACDB-1539245F1EFE

Q36708123-4AB05D3F-B61F-42C4-B7CF-78C50EE26140

Q36708123-4B5DE538-8C0F-4407-85B2-438D5D254C5A

P2888

Q36708123-D7F114BB-750D-49B3-B0A2-6F2A02F8A5CD

P304

Q36708123-B9A9AC49-B6BA-4CB6-A664-7E41C37D391F

P31

Q36708123-F18DD943-2B86-404B-8D8C-B4D73F5643FD

P356

Q36708123-FFEC186D-8BC0-45E6-8C6A-8CB34B65C8B0

P433

Q36708123-490F94FD-B118-4DEF-ABA7-7FFC4D1929AF

P478

Q36708123-9DCD6E4C-1FEF-4E07-B5B9-BBC4E9D93D0F

P50

Q36708123-74E02B68-BC46-47E7-BA7F-5955D5CF27D6

P577

Q36708123-F971C7AA-42FA-4811-A078-5EB4D2047D60

P5875

Q36708123-2F8D4554-4448-42EA-B687-B184738FDF68

P698

Q36708123-A1036046-B0E5-4EFE-84A3-94C763692A91

P921

Q36708123-53B16745-8D6F-4175-9F39-5C462AB981BE

Q36708123-82102A56-7C2E-48D1-8213-A42A210B4EBD

P932

Q36708123-37931CAD-87FB-4897-A26C-F6DFC0E72CF6

P356

S00702-012-0801-3

P1433

Journal of Neural Transmission

P1476

Cerebrospinal fluid amyloid-β ...... not in frontotemporal dementia

@en

P2093

Eckart Rüther

http://www.w3.org/2001/XMLSchema#string

Hermann Esselmann

http://www.w3.org/2001/XMLSchema#string

Marion Gallus

http://www.w3.org/2001/XMLSchema#string

Mirko Bibl

http://www.w3.org/2001/XMLSchema#string

Stefanie Wolf

http://www.w3.org/2001/XMLSchema#string

Volker Welge

http://www.w3.org/2001/XMLSchema#string

P2860

A window into the heterogeneity of human cerebrospinal fluid Aβ peptides

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein

Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria

Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells.

Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation.

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry.

High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain.

Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry.

P2888

s00702-012-0801-3

P304

805-813

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00702-012-0801-3

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-04-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224820677

http://www.w3.org/2001/XMLSchema#string

P698

22527776

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

cerebrospinal fluid

P932

3605494

http://www.w3.org/2001/XMLSchema#string